StockTipsArenaBeta

BUY Mankind Pharma Limited — Kavita Jain, Arihant Capital Markets

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byKavita Jain, Arihant Capital MarketsHorizon: NA (inferred Swing (≤2wk))10 Jun 2026via CNBC Awaaz.

Entry₹2,400Stated
Target₹2,450
Total upside +2.08% (call closed)
Stop loss₹2,360-1.67% risk
Exit₹2,36011 Jun 2026, 9:15 am
Stop-loss hit-1.67%
Follow Kavita Jain for new calls(45% target hit, 71 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:33 pm IST
3 supporting1 neutral0 opposing
Supports the BUY call (3)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·3 Jun · 1w ago

Mankind Pharma Limited, through its subsidiary, acquired the remaining 10% stake in Upakarma Ayurveda Private Limited, making Upakarma a wholly-owned subsidiary. This acquisition aims to improve opera

NSE · Acquisition·2 Jun · 1w ago

(opens in new tab)

Mankind Pharma Ltd has informed about a stake acquisition by one of its wholly-owned subsidiary companies.

BSE · Company Update·2 Jun · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Mankind Pharma to meet investors in Mumbai on June 1-2

NewsGoogle News·27 May · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Kavita Jain, Arihant Capital Markets

Every call and its outcome